Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$45.97
-1.1%
$42.45
$16.91
$48.22
$787.53M1.51146,702 shs119,227 shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$3.94
-4.6%
$3.79
$2.37
$7.63
$525.43M1.36871,849 shs974,107 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.35
+0.2%
$11.11
$3.91
$14.42
$918.80M1.93751,126 shs665,102 shs
10x Genomics stock logo
TXG
10x Genomics
$12.64
-3.2%
$13.21
$6.78
$24.38
$1.63B22.15 million shs2.52 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
-1.08%+0.94%-0.43%+35.89%+143.74%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-4.60%-1.99%-5.52%+22.36%-28.23%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+0.15%-4.71%+21.25%+47.84%+62.41%
10x Genomics stock logo
TXG
10x Genomics
-3.22%-9.46%-6.85%+21.42%-42.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$45.97
-1.1%
$42.45
$16.91
$48.22
$787.53M1.51146,702 shs119,227 shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$3.94
-4.6%
$3.79
$2.37
$7.63
$525.43M1.36871,849 shs974,107 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.35
+0.2%
$11.11
$3.91
$14.42
$918.80M1.93751,126 shs665,102 shs
10x Genomics stock logo
TXG
10x Genomics
$12.64
-3.2%
$13.21
$6.78
$24.38
$1.63B22.15 million shs2.52 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
-1.08%+0.94%-0.43%+35.89%+143.74%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-4.60%-1.99%-5.52%+22.36%-28.23%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+0.15%-4.71%+21.25%+47.84%+62.41%
10x Genomics stock logo
TXG
10x Genomics
-3.22%-9.46%-6.85%+21.42%-42.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allient Inc. stock logo
ALNT
Allient
2.00
Hold$35.00-23.86% Downside
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.20
Hold$5.6042.13% Upside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$26.86101.18% Upside
10x Genomics stock logo
TXG
10x Genomics
2.33
Hold$13.658.02% Upside

Current Analyst Ratings Breakdown

Latest CTKB, TXG, EYPT, and ALNT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
10x Genomics stock logo
TXG
10x Genomics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$15.00
9/5/2025
10x Genomics stock logo
TXG
10x Genomics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/30/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated Rating
8/14/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated Rating
8/12/2025
10x Genomics stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$18.00 ➝ $17.00
8/11/2025
10x Genomics stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$16.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$12.00 ➝ $13.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetHold$14.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$13.00 ➝ $15.00
8/7/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
8/6/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$22.00 ➝ $23.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allient Inc. stock logo
ALNT
Allient
$529.97M1.47$3.00 per share15.32$15.72 per share2.92
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$200.45M2.50$0.03 per share119.01$3.07 per share1.28
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M21.27N/AN/A$4.93 per share2.71
10x Genomics stock logo
TXG
10x Genomics
$610.78M2.58N/AN/A$5.81 per share2.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allient Inc. stock logo
ALNT
Allient
$13.17M$0.8653.4525.12N/A2.75%9.97%4.67%11/5/2025 (Estimated)
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$6.02M-$0.05N/AN/A-3.27%-1.66%-1.30%11/4/2025 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.68N/AN/AN/A-337.93%-63.80%-50.72%11/6/2025 (Estimated)
10x Genomics stock logo
TXG
10x Genomics
-$182.63M-$0.70N/AN/AN/A-13.13%-12.88%-10.03%10/27/2025 (Estimated)

Latest CTKB, TXG, EYPT, and ALNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.35$0.28+$0.63$0.28$139.36 million$172.91 million
8/6/2025Q2 2025
Allient Inc. stock logo
ALNT
Allient
$0.48$0.57+$0.09$0.34$132.89 million$139.58 million
8/6/2025Q2 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.67-$0.85-$0.18-$0.85$6.82 million$5.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allient Inc. stock logo
ALNT
Allient
$0.120.26%N/A13.95%N/A
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest CTKB, TXG, EYPT, and ALNT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Allient Inc. stock logo
ALNT
Allient
quarterly$0.030.3%8/21/20258/21/20259/4/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allient Inc. stock logo
ALNT
Allient
0.70
3.74
2.17
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
5.22
4.55
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
8.00
7.91
10x Genomics stock logo
TXG
10x Genomics
N/A
5.84
5.23

Institutional Ownership

CompanyInstitutional Ownership
Allient Inc. stock logo
ALNT
Allient
61.57%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Allient Inc. stock logo
ALNT
Allient
15.60%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
10.33%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
10x Genomics stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allient Inc. stock logo
ALNT
Allient
2,52516.95 million14.30 millionOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500127.22 million114.08 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.93 million65.85 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240124.49 million112.80 millionOptionable

Recent News About These Companies

10x Genomics (NASDAQ:TXG) Now Covered by Analysts at Piper Sandler
Piper Sandler Begins Coverage on 10x Genomics (NASDAQ:TXG)
10x Genomics (TXG) Stock Trades Down, Here Is Why
10x Genomics $TXG Shares Bought by Voleon Capital Management LP
Expert Outlook: 10x Genomics Through The Eyes Of 6 Analysts
10x Genomics (TXG) Stock Is Up, What You Need To Know
2 Cash-Heavy Stocks to Own for Decades and 1 We Turn Down
Caxton Associates LLP Takes Position in 10x Genomics $TXG
10x Genomics $TXG Shares Purchased by PDT Partners LLC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allient stock logo

Allient NASDAQ:ALNT

$45.97 -0.50 (-1.08%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$45.18 -0.79 (-1.72%)
As of 09/12/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allient Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, authorized manufacturers' representatives, and distributors. The company was formerly known as Allied Motion Technologies Inc. and changed its name to Allient Inc. in August 2023. Allient Inc. was incorporated in 1962 and is headquartered in Amherst, New York.

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$3.94 -0.19 (-4.60%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$3.94 0.00 (0.00%)
As of 09/12/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$13.35 +0.02 (+0.15%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$13.35 0.00 (0.00%)
As of 09/12/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$12.64 -0.42 (-3.22%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$12.75 +0.11 (+0.90%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.